<DOC>
	<DOCNO>NCT02153268</DOCNO>
	<brief_summary>Phase I/II open label first human single center clinical study , evaluate safety efficacy BonoFill bone filler contain patient ( autologous ) adipose tissue derive cell ( HATDCs ) reconstruct Bone Void maxillofacial area approximately 6 month follow implantation follow two clinical indication : 1 . Bone augmentation ( e.g . sinus augmentation ) 2 . Bone graft removal cyst jaw</brief_summary>
	<brief_title>Filling Bone Defects/Voids With Autologous BonoFill For Maxillofacial Bone Regeneration</brief_title>
	<detailed_description>Primary endpoint : The implantation BonoFill maxillary mandible defect/void safe following condition : No chronic bone infection ( Osteomyelitis ) ; significant change complete blood count ( CBC ) general health . Secondary endpoint : The implantation BonoFill maxillary mandible void efficient follow condition : Following BonoFill implantation , bone regeneration operate site significantly accelerate . Also , bone defects/voids fill significant amount bone tissue .</detailed_description>
	<criteria>The inclusion criterion define eligible subject divide two group accord clinical indication : Sinus augmentation Subjects general good health opinion investigator determine medical history , vital sign physical examination safety lab test Subjects rehabilitation dentist rehabilitation program Up date panoramic XRay . Subjects provide write informed consent participate study , able understand study procedure agree follow procedure Healthy condition Maxillary Sinuses Oral Mucosa . Subantral bone least 4 mm measure CBCT/CT . Have good oral hygiene condition per investigator discretion . Bone graft removal cyst jaw Healthy subject . Subjects rehabilitation dental treatment . Limited cyst diagnose : radicular cyst , residual cyst , congenital cyst , developmental acquire cyst . Subjects refer oral &amp; maxillofacial Dpt removal cyst diagnosis cyst type . Healthy bone determine Xray . Have good oral hygiene condition . Subject participate clinical study . Subject able read understand sign inform consent Subjects record medical history disease : diabetes mellitus , heart disease , renal failure , osteoporosis . Subject treated systemic steroid treatment Subjects know autoimmune disease , : Addison 's disease Celiac disease sprue ( glutensensitive enteropathy ) , Dermatomyositis Graves disease , Hashimoto 's thyroiditis , Multiple sclerosis , Myasthenia gravis Pernicious anemia , Reactive arthritis , Rheumatoid arthritis , Sjogren syndrome Systemic lupus erythematosus , Type I diabetes . Subjects Vitiligo and/or know scar heal problem ( keloid formation ) . Subjects treat anticoagulation medication ( Coumadin , Plavix similar medication ) Subjects treated Oral Bisphosphonate drug ( Fosalan similar medication ) Subjects history Chemotherapy Radiotherapy treatment In case sinus augmentation Unhealthy condition Maxillary Sinuses . Subjects current active infection illness Subjects participate another clinical trial 30 day prior study period Pregnant lactate woman . Pregnancy verify urine test screen Known history significant medical disorder , investigator 's judgment contraindicate subject 's participation Subjects know allergy anesthesia Positive serology either HIV , hepatitis B hepatitis C Abnormal clinically significant per investigator 's judgment laboratory test exam finding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>BonoFill</keyword>
	<keyword>bone filler</keyword>
	<keyword>autologous adipose tissue derive cell ( HATDCs )</keyword>
	<keyword>Bone augmentation</keyword>
	<keyword>sinus augmentation</keyword>
	<keyword>Bone graft removal cyst jaw</keyword>
</DOC>